Amarin Corporation plc (NASDAQ:AMRN) Cantor Virtual Global Healthcare Conference Call September 16, 2020 11:20 AM ET
Company Participants
John Thero - Chief Executive Officer
Conference Call Participants
Louise Chen - Cantor Fitzgerald
Louise Chen
Hi, I'm Louise Chen, the large cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Amarin. Amarin launched VASCEPA in first quarter of 2020 in the U.S. as the first and only FDA approved drug to reduce persistent cardiovascular risk beyond stem therapy in studied patients. We think the peak sales potential of this global opportunity is still underappreciated. Therefore, we're very excited to have with us today CEO of Amarin, John Thero to discuss Amarin’s go forward strategy for VASCEPA.
John, for investors that are new to the story, can you please walk us through the history of the company and how you came to be and what do you see as Amarin’s differentiated offering in the years to come?
John Thero
Louise, first, thank you for invitation to participate in this virtual conference. I should, you know, comment just from the start that in conjunction with this presentation, I will be making forward-looking statements that are risks involved with all such forward looking statements, and anybody considering investing in the company should review our risk factors in our SEC filings before in investing.
For people who are new to this, you know, Amarin’s lead product is a product called VASCEPA. It's in the cardiovascular space. When we started working on VASCEPA, you know more, than a decade ago, we looked at, you know, cardiovascular disease as being an enormous and growing, you know, challenge. It's a leading cause of death in most of the world and we looked at solutions out there which include, you know, drugs for, you know, hypertension and drugs for cholesterol management, etcetera. But, you know, clearly those therapies aren't
- Read more current AMRN analysis and news
- View all earnings call transcripts